Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Finding stocks with a moonshot potential is like finding gold — you must know where to search, what criteria to use in a stock screener and how to make a narrow list of selections from that info. Even the best penny ...
LAKE FOREST, Ill., June 01, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced its participation in the LD Micro Invitatio...
The company has made giant strides in putting its financials in order, getting rid of almost $1B in debt and its net debt has been all but eliminated. We believe more is to come as the company's all-digital business model is very scalable. There are some risks, the company will ha...
RALEIGH, NC / ACCESSWIRE / May 16, 2022 / The Spring into Action- Best Ideas Virtual Investor Conference will take place on May 16 th - 20 th , 2022, where 36 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual webcast to a global investor audience. The Spring in...
The following slide deck was published by Assertio Holdings, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Assertio Holdings, Inc. 2022 Q1 - Results - Earnings Call Presentation
Gainers: Biohaven Pharmaceutical (BHVN) +71%. AdaptHealth (AHCO) +31%. Evaxion Biotech (EVAX) +25%. Assertio (ASRT) +22%. Haemonetics (HAE) +16%. Losers: Bausch Health (BHC) -26%. GoodRx (GDRX) -24%. Akanda (AKAN) -21%. Novavax ...
Assertio Holdings, Inc. (ASRT) Q1 2022 Earnings Conference Call May 09, 2022 04:30 PM ET Company Participants Max Nemmers - Head, Investor Relations and Administration Daniel Peisert - President & CEO Paul Schwichtenberg - SVP & CFO Conference Call Participants Scott Weis - Semco Capi...
Assertio Therapeutics press release (NASDAQ:ASRT): Q1 Non-GAAP EPS of $0.38. Revenue of $36.54M (+36.1% Y/Y) beats by $3.48M. Shares +20.7%. 2022 Financial Guidance Net Product Sales (GAAP): $126.0 Million to $136.0 Million Adjusted EBITDA (Non-GAAP): $66.0 Million to $74.0 Million ...
Reaffirms Full Year Net Product Sales and Raises Full Year Non-GAAP Adjusted EBITDA Guidance Net Product Sales Up 37% and Non-GAAP Adjusted EBITDA Up 52% Compared to Prior Year Quarter Quarterly Net Cash Flows from Operating Activities of $27.4 Million LA...
ADES, AGM, AIV, AKBA, ALCO, ALTO, AMC, AMPH, AMWL, ANGI, APPF, APTO, ARCT, AROC, ASLE, ASRT, ATER, AVIR, AZTA, BATL, BHF, BLFS, BLI, BLNK, BODY, OTCPK:BOWFF, BRMK, BRT, BW, BWXT, CAPL, CARA, CARG, CHMI, CLAR, CLOV, CNNE, CSTL, OTCPK:CURLF, DDD, DHT, DNB, ENTA, EQH, EVBG, FCRD, FF, FGEN, FLL, ...
News, Short Squeeze, Breakout and More Instantly...
Assertio Therapeutics Inc. Company Name:
ASRT Stock Symbol:
NASDAQ Market:
Assertio Therapeutics Inc. Website:
LAKE FOREST, Ill., July 24, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that it will rel...
2024-07-03 07:15:03 ET H.C. Wainwright analyst issues BUY recommendation for ASRT on July 3, 2024 06:04AM ET. ASRT was trading at $1.15 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommendati...
LAKE FOREST, Ill., June 05, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced that Ajay Patel, Chief...